已收盘 10-04 16:00:00 美东时间
+0.130
+1.99%
Larimar Therapeutics (NASDAQ:LRMR) was started at outperform by Wedbush based on the company’s drug candidate nonlabofusp for Friedreich’s ataxia, or FA. Wedbush said that despite the success of Bioge...
10-03 23:26
Jones Research started coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing the company’s lead asset nomlabofusp for the treatment of Friedreich’s Ataxia, or FA. Jones said that al...
09-13 03:58
数据中心运营商APLD暴涨近66%!公司获英伟达及其他投资者1.6亿美元融资;蔚来涨逾14%,Q2营收同比增长99%,Q3交付指引超过市场预期>>
09-06 19:12
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 poin...
09-06 01:44
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-04 17:41
Larimar Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Tar...
09-04 12:02
Just because a business does not make any money, does not mean that the stock w...
08-09 18:06
Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.34. As of June 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $226.1 million, More on Larimar ...
08-07 21:19
Larimar Therapeutics Inc: Cash Equivalents and Marketable Securities as of June...
08-07 19:10
Larimar Therapeutics Q2 Income From Operations USD -24.599 Million
08-07 19:00